DE60329589D1 - Antikörper gegen den humanen "insulin-like" wachstumsfaktor - Google Patents

Antikörper gegen den humanen "insulin-like" wachstumsfaktor

Info

Publication number
DE60329589D1
DE60329589D1 DE60329589T DE60329589T DE60329589D1 DE 60329589 D1 DE60329589 D1 DE 60329589D1 DE 60329589 T DE60329589 T DE 60329589T DE 60329589 T DE60329589 T DE 60329589T DE 60329589 D1 DE60329589 D1 DE 60329589D1
Authority
DE
Germany
Prior art keywords
higf
antibodies
igf
human
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60329589T
Other languages
English (en)
Inventor
Kenya Shitara
Kazuyasu Nakamura
Akiko Furuya
Rinpei Niwa
Yuji Ohki
Nobuo Hanai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Application granted granted Critical
Publication of DE60329589D1 publication Critical patent/DE60329589D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
DE60329589T 2002-04-30 2003-04-30 Antikörper gegen den humanen "insulin-like" wachstumsfaktor Expired - Lifetime DE60329589D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002129046 2002-04-30
PCT/JP2003/005505 WO2003093317A1 (fr) 2002-04-30 2003-04-30 Anticorps pour facteur de croissance humain semblable a l'insuline

Publications (1)

Publication Number Publication Date
DE60329589D1 true DE60329589D1 (de) 2009-11-19

Family

ID=29397291

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60329589T Expired - Lifetime DE60329589D1 (de) 2002-04-30 2003-04-30 Antikörper gegen den humanen "insulin-like" wachstumsfaktor

Country Status (9)

Country Link
US (1) US7438911B2 (de)
EP (1) EP1505075B1 (de)
JP (1) JP4335130B2 (de)
AT (1) ATE444972T1 (de)
AU (1) AU2003231554A1 (de)
CA (1) CA2483848C (de)
DE (1) DE60329589D1 (de)
ES (1) ES2333952T3 (de)
WO (1) WO2003093317A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS20060099A (en) 2003-08-13 2008-08-07 Pfizer Products Inc., Modified human igf-1r antibodies
JPWO2005018671A1 (ja) * 2003-08-21 2006-10-19 協和醗酵工業株式会社 癌転移阻害剤
ATE492562T1 (de) * 2003-09-24 2011-01-15 Kyowa Hakko Kirin Co Ltd Rekombinanter antikörper gegen humanen insulin- like growth factor
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
DE602005025685D1 (de) 2004-12-03 2011-02-10 Schering Corp Biologische marker zur vorauswahl von patienten für die anti-igf1r-therapie
SI1979001T1 (sl) * 2005-12-13 2012-08-31 Medimmune Ltd Vezni proteini specifiäśno za inzulinu podobne rastne faktorje in njih uporaba
ATE552853T1 (de) * 2005-12-13 2012-04-15 Medimmune Ltd Proteine die spezifisch insulin-ähnliche wachstumsfaktoren binden, und deren anwendungen
WO2007118214A2 (en) * 2006-04-07 2007-10-18 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Antibody compositions and methods for treatment of neoplastic disease
WO2008152422A2 (en) * 2007-06-12 2008-12-18 Astrazeneca Ab Binding proteins specific for insulin-like growth factors and uses thereof-909
PE20090368A1 (es) * 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
US9029508B2 (en) 2008-04-29 2015-05-12 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
JP5734180B2 (ja) * 2008-05-09 2015-06-17 ダイアックス コーポレーション Ｉｇｆ−ｉｉ／ｉｇｆ−ｉｉｅ結合タンパク質
EP3002299A1 (de) 2008-06-03 2016-04-06 AbbVie Inc. Dual-variable- domain-immunglobuline und ihre verwendungen
CN102112494A (zh) 2008-06-03 2011-06-29 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途
KR20110031369A (ko) 2008-07-08 2011-03-25 아보트 러보러터리즈 프로스타글란딘 ｅ2 이원 가변 도메인 면역글로불린 및 이의 용도
CA2740440A1 (en) * 2008-10-14 2010-04-22 Dyax Corp. Use of igf-ii/igf-iie binding proteins for the treatment and prevention of systemic sclerosis-associated pulmonary fibrosis
SI2376116T1 (sl) 2008-12-12 2016-03-31 Boehringer Ingelheim International Gmbh Anti-IGF protitelesa
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
JP2013503607A (ja) * 2009-09-01 2013-02-04 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリンおよびその使用
AU2010289677B2 (en) 2009-09-03 2014-07-31 Merck Sharp & Dohme Llc Anti-GITR antibodies
CA2774953A1 (en) 2009-10-07 2011-04-14 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Human domain antibodies against components of the human insulin-like growth factor (igf) system
AR078651A1 (es) * 2009-10-15 2011-11-23 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CA2785964C (en) * 2009-12-29 2021-03-30 Kyowa Hakko Kirin Co., Ltd. Anti-cd27 antibody
NZ607480A (en) 2010-08-03 2014-10-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2608803A4 (de) 2010-08-26 2014-01-15 Abbvie Inc Immunglobuline mit zweifacher variabler domäne und ihre verwendung
KR20130118892A (ko) * 2010-11-02 2013-10-30 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
WO2012142164A1 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
CN102520190B (zh) * 2011-12-15 2014-03-05 中国人民解放军总医院 一种人胰岛素样生长因子ⅱ酶联免疫分析检测试剂盒
EP2797955A2 (de) 2011-12-30 2014-11-05 AbbVie Inc. Immunglobuline mit zweifacher variabler domäne gegen il-13 und/oder il-17
SG11201503412RA (en) 2012-11-01 2015-05-28 Abbvie Inc Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
MX2015013166A (es) 2013-03-15 2015-12-11 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
TWI695013B (zh) * 2014-04-10 2020-06-01 台灣浩鼎生技股份有限公司 抗體、產生該抗體之融合瘤、包含該抗體之藥學組成物及其用途
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985000831A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
AU1232188A (en) 1987-05-29 1988-12-01 Mallinckrodt, Inc. Novel pair of monoclonal antibodies to insulin-like growth factor i permits immunometric assay for igf-i
CA2058041A1 (en) * 1990-06-27 1991-12-28 Katsuichi Sakano Anti-igf-ii monoclonal antibody
EP0700994A1 (de) * 1994-03-23 1996-03-13 Japan Clinical Laboratories Monoklonale anti-igf-i antikörper
JPWO2005018671A1 (ja) * 2003-08-21 2006-10-19 協和醗酵工業株式会社 癌転移阻害剤

Also Published As

Publication number Publication date
CA2483848A1 (en) 2003-11-13
US20060165695A1 (en) 2006-07-27
AU2003231554A1 (en) 2003-11-17
WO2003093317A1 (fr) 2003-11-13
JP4335130B2 (ja) 2009-09-30
EP1505075A4 (de) 2006-06-21
JPWO2003093317A1 (ja) 2005-09-08
CA2483848C (en) 2012-08-21
ES2333952T3 (es) 2010-03-03
US7438911B2 (en) 2008-10-21
ATE444972T1 (de) 2009-10-15
EP1505075B1 (de) 2009-10-07
EP1505075A1 (de) 2005-02-09

Similar Documents

Publication Publication Date Title
DE60329589D1 (de) Antikörper gegen den humanen "insulin-like" wachstumsfaktor
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
EP2628751A3 (de) Bindungselemente für interleukin-6 und deren verwendung
WO2005058961A3 (en) Antibodies specific for human galanin, and uses thereof
SG147444A1 (en) Anti-ox40l antibodies
WO2008036341A3 (en) Compositions and methods relating to glucagon receptor antibodies
MY149630A (en) Antibodies against amyloid-beta peptide
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
MX2007000304A (es) Metodo de tratamiento de enfermedad de almacenamiento de glucogeno o polisacaridos.
MX2009006066A (es) Tratamiento de cerdos con el antigeno pcv.
IN2005DE03350A (de)
EP2535353A8 (de) An hGM-CSF bindende monoklonale Antikörper und medizinische Zusammensetzungen damit
UA90467C2 (ru) Применение пептидных соединений для лечения боли при болезненой диабетической невропатии
RS20060234A (en) Fully human antibodies against human 4-1bb (cd137)
TW200716612A (en) Pyrimidine compounds
WO2007079202A3 (en) Treatment for acute lymhoblastic leukemia
NZ575245A (en) Targeted binding agents directed to pdgfr-alpha and uses thereof
ATE456955T1 (de) Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen
WO2010075280A3 (en) Coumarin-based compounds for the treatment of alzheimer's disease and cancer
BRPI0409359A (pt) análogos quiméricos de somatostatina-dopamina
CY1116938T1 (el) Αναπληρωτικη θεραπεια της ασθενειας huntington και αλλων ασθενειων πολυγλουταμiνης
BR0307629A (pt) Métodos e composições para tratar condições hiperproliferativas
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης
WO2010036567A3 (en) Harmine compounds for promoting bone growth
HK1097762A1 (en) Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients

Legal Events

Date Code Title Description
8364 No opposition during term of opposition